CL2024000062A1 - Composición farmacéutica de virus no encapsulado - Google Patents

Composición farmacéutica de virus no encapsulado

Info

Publication number
CL2024000062A1
CL2024000062A1 CL2024000062A CL2024000062A CL2024000062A1 CL 2024000062 A1 CL2024000062 A1 CL 2024000062A1 CL 2024000062 A CL2024000062 A CL 2024000062A CL 2024000062 A CL2024000062 A CL 2024000062A CL 2024000062 A1 CL2024000062 A1 CL 2024000062A1
Authority
CL
Chile
Prior art keywords
enveloped virus
pharmaceutical composition
compositions
recombinant
raav
Prior art date
Application number
CL2024000062A
Other languages
English (en)
Spanish (es)
Inventor
Valentinovich MOROZOV Dmitry
Igorevna Fedorenko Lina
Aleksandrovna Lomkova Ekaterina
Olegovich Iakovlev Aleksandr
Aleksandrovna Sozonova Aleksandra
Konstantinovna Dvoriankina Marina
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2860958C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CL2024000062A1 publication Critical patent/CL2024000062A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2024000062A 2021-07-08 2024-01-08 Composición farmacéutica de virus no encapsulado CL2024000062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021120143A RU2860958C2 (ru) 2021-07-08 Фармацевтическая композиция безоболочечного вируса

Publications (1)

Publication Number Publication Date
CL2024000062A1 true CL2024000062A1 (es) 2024-06-14

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000062A CL2024000062A1 (es) 2021-07-08 2024-01-08 Composición farmacéutica de virus no encapsulado

Country Status (12)

Country Link
EP (1) EP4367252A4 (fr)
CN (1) CN117999353A (fr)
AR (1) AR126417A1 (fr)
CL (1) CL2024000062A1 (fr)
CO (1) CO2024000073A2 (fr)
CR (1) CR20240004A (fr)
EC (1) ECSP24001599A (fr)
JO (1) JOP20240003A1 (fr)
MA (1) MA63861A1 (fr)
MX (1) MX2024000472A (fr)
WO (1) WO2023282796A2 (fr)
ZA (1) ZA202400124B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503893A (ja) * 2023-01-19 2026-02-02 ユニキュアー バイオファーマ ビー.ブイ. 遺伝子送達媒体の医薬製剤
CN122029285A (zh) * 2023-09-06 2026-05-12 迪纳柯公司 用aav基因治疗载体和治疗调配物治疗肥厚性心肌病的方法
WO2025114524A1 (fr) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations pour produits médicamenteux viraux
WO2025263459A1 (fr) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Composition biopharmaceutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012222150A1 (en) * 2011-02-24 2013-09-26 Paxvax, Inc. Formulations useful for spray drying vaccines
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
CN105530917B (zh) * 2013-09-19 2020-06-05 扬森疫苗与预防公司 改进的腺病毒配制品
PT3534922T (pt) * 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado
JP2021530548A (ja) * 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法

Also Published As

Publication number Publication date
CO2024000073A2 (es) 2024-04-29
JOP20240003A1 (ar) 2024-01-08
EP4367252A2 (fr) 2024-05-15
CR20240004A (es) 2024-06-11
AR126417A1 (es) 2023-10-11
WO2023282796A3 (fr) 2023-02-16
WO2023282796A2 (fr) 2023-01-12
MA63861A1 (fr) 2024-10-31
ECSP24001599A (es) 2024-02-29
ZA202400124B (en) 2024-11-27
EP4367252A4 (fr) 2025-04-30
CN117999353A (zh) 2024-05-07
MX2024000472A (es) 2024-02-12

Similar Documents

Publication Publication Date Title
CR20240004A (es) Composición farmacéutica de virus no encapsulado
CL2018003196A1 (es) Cápsides variantes de virus adenoasociados y métodos de uso de estas.
MX2021004431A (es) Procesos novedosos.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
WO2015128403A3 (fr) Nouveaux dérivés de l'insuline et leurs utilisations médicales
BR112015019412A2 (pt) inibidores de bace1
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
WO2022192594A3 (fr) Molécules d'acide nucléique et vaccins les comprenant pour la prévention et le traitement d'infections à coronavirus et de maladie
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
MX377333B (es) Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos.
MY208364A (en) Novel insulin analogues and uses thereof
PH12022550238A1 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
BR112019024796A2 (pt) Peptídeos e usos dos mesmos como agentes antivirais
MX2024009890A (es) Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
GEAP202516788A (en) Pharmaceutical composition of non-enveloped virus
BR112017015474A2 (pt) inibidores de bace1
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
JOP20220313A1 (ar) تركيبة دوائية مائية من الليفيليماب وإستخدامها
MX2024001541A (es) Composiciones proteicas para el tratamiento de enfermedades inflamatorias.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа